Latest news with #PNS
Yahoo
2 days ago
- Business
- Yahoo
Walnut Hill Study Exposes Systemic Medicare Advantage Barriers Causing Delays, Denials, and Patient Abandonment
DALLAS, June 3, 2025 /PRNewswire/ -- Walnut Hill Medical has released findings from its MAD (Medicare Advantage Denial) Study, revealing that Medicare Advantage plans are systematically delaying or denying access to a non-opioid, non-steroidal chronic pain treatment: Peripheral Nerve Stimulation (PNS). Based on a proprietary dataset of 1,210 Medicare Advantage patients who sought prior authorization for PNS in 2024, the study paints a troubling picture—raising urgent concerns about transparency, equity, and access in America's most popular form of Medicare coverage. "Prior authorization isn't just a bureaucratic hurdle—it's being weaponized to deter care," said Chris Hanna, CEO of Walnut Hill Medical. "Transparency is the first step toward accountability." Understanding the Issue: What Is Medicare Advantage and Prior Authorization? Medicare Advantage (Medicare Part C) is a private alternative to traditional Medicare, now covering over half of all Medicare beneficiaries. These plans are managed by private insurers and often tout extra benefits—but they also impose stricter controls, including prior authorization (PA) requirements for many medical services. Prior authorization requires providers to obtain insurer approval before delivering care. While designed to ensure medical necessity and control costs, PA can also result in significant care delays—or outright denials. The 2022 Warning That Went Unheeded In 2022, the Office of Inspector General (OIG) found that 13% of denied services in Medicare Advantage met Medicare coverage criteria and should have been approved. The OIG warned that plans may be inappropriately restricting access to necessary care. Walnut Hill's 2024 data show the problem is even worse—especially for patients seeking advanced therapies like PNS. Key Findings: Denials, Drop-Off, and Delays in Pain Treatment Access PNS is a minimally invasive, FDA-cleared therapy for chronic pain. Walnut Hill's study found: 29% of patients were denied on their first prior authorization attempt—more than twice the OIG's 2022 benchmark. 28% of patients abandoned care after an initial denial—never appealing or resubmitting. Among those who appealed: 56% had their denial overturned. 69% who escalated to a Medicare hearing (OMHA) were approved. "This isn't just inefficiency," Hanna said. "It's a sorting mechanism that weeds out patients without time, resources, or strong clinical advocates." The Cost of Denial: Financial Incentives and Patient Harm Of the 1,210 patients studied, 210 were denied and never received their PNS therapy. Based on 2024 Medicare Advantage reimbursement rates, Medicare Advantage plans withheld $6.2 million worth of care from patients—highlighting how administrative attrition reduces cost at the patient's expense. A Call for Oversight and Reform "Medicare Advantage now covers the majority of eligible seniors," said Hanna. "With that dominance must come responsibility. Our data show that without reform, prior authorization becomes a silent gatekeeper—not just delaying care but denying it altogether." Walnut Hill is urging lawmakers to strengthen transparency and accountability provisions in the bipartisan Improving Seniors' Timely Access to Care Act of 2025, introduced by Rep. Mike Kelly (R-PA). Download the Full Report The complete MAD Study, including detailed methodology, statistics, and patient-level analysis, is available here: About Walnut Hill Medical Walnut Hill Medical partners with medical device companies, providers, life sciences organizations, and patients to deliver expert reimbursement strategy, health policy insights, and seamless prior authorization support. Their mission: Empower innovators to deliver care, enable doctors to focus on patients, and help patients access the therapies they need—without administrative barriers. Resources: Walnut Hill Medical MAD Study: Full OIG Report: Improving Seniors' Timely Access to Care Act of 2025: Media Contact:Grace CuillierDirector of StrategyGCuillier@ View original content to download multimedia: SOURCE Walnut Hill Medical Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Straits Times
2 days ago
- General
- Straits Times
Servicemen's contributions recognised at Police Day Parade
SINGAPORE – 2025 marks the 50th anniversary of Police National Service (PNS), which was conceived after a terror incident in Singapore. And PNS officers have contributed much to keeping the country safe, said Mr Edwin Tong, who was attending his first police event as the second minister for Home Affairs. He made these comments on June 3 at the Police Day observance ceremony, which took place at the Home Team Academy at Choa Chu Kang. Mr Tong, who is also the Minister for Law, thanked police officers past and present for their sacrifices . He said: 'Policing, we know, is an inherently challenging profession. Threats to our public order and security remain ever present, and your operating environment is increasingly complex and highly demanding. 'Thank you for your steadfast dedication round the clock, for putting your lives on the line to uphold and enforce our laws, to keep Singapore safe and secure.' PNS was introduced in 1975, a year after the Laju incident, in which four armed attackers targeted the oil refinery on Pulau Bukom and hijacked a ferry, called the Laju, with civilians onboard. It was Singapore's first brush with international terrorism. The hostages were released after a group of 13 'guarantors', including former President S R Nathan, boarded the vessel to take their place. Said Mr Tong: 'We recognised the urgent need to strengthen the protection of our vital installations. And so, full-time PNS was introduced — where their role was established to serve as a credible deterrent against future threats.' PNS officers now work with regular police officers to perform frontline duties such as patrolling the streets and responding to incidents. Mr Tong said that in the recent general election more than 8,000 PNS officers were recalled and deployed at rallies, polling stations and counting centres to control crowds and ensure public safety. Two batches of NSCOs have been deployed to the Anti-Scam Command and Cybercrime Command. NSCOs detect and disrupt cybercrimes and scams, including operating the ScamShield dashboard to review user-reported scams. Said Mr Tong: 'They are at the forefront of safeguarding Singapore's digital space as our new generation of cyber defenders.' Scams and cybercrimes account for the majority of crime in Singapore. A record $1.1 billion was lost here to scams in 2024. To commemorate the 50 years of PNS, Mr Tong announced that SPF will be holding a series of events including the launch of a PNS50 time capsule, and a graduation parade for the 200th PNSF intake. Said Mr Tong: 'To our PNS officers, both past and present, thank you very much for stepping up to serve the nation, taking your training seriously, and discharging your duties with the utmost professionalism. 'You have played an invaluable role in keeping Singapore safe and secure. To your families and employers, thank you too for your support as our PNSmen perform their duties.' Police day also celebrates the 100th anniversary of the Singapore Police Force (SPF) band. Established in 1925, it is the oldest uniformed band in Singapore, consisting of more than 60 officers. In recognition of their achievements in 2024, the police Central Division was lauded as the Best Land Division during the ceremony. It is the second time it has received the award, after winning it in 2018. Deputy Assistant Commissioner Wong Keng Hoe, commander of the Police Central Division, received the award from Mr Tong during the ceremony. DAC Wong told the media in an interview on June 2 that the award was due to the efforts of his predecessors and his officers on the ground. In 2024, the Central Division was responsible for ensuring the safety of the public during the Marina Bay Countdown 2025 and taking down scam syndicates who were trying to cheat retailers of electronic devices and jewellery. The runners-up for the Best Land Division were Clementi Police Division and Jurong Police Division. Tanglin Police Division was named Best NS Operationally Ready Unit, with Jurong Police Division and Woodlands Police Division achieving second and third place respectively. The award recognises national service divisions for their management of NS men in fitness, operations and recall rates. Join ST's WhatsApp Channel and get the latest news and must-reads.
Yahoo
28-05-2025
- Business
- Yahoo
SPR Announces Publication of Sustained Chronic Shoulder Pain Outcomes Up to Five Years Post-Treatment
83 percent required no subsequent interventions, 87 percent of those patients reported ongoing improvement CLEVELAND, May 28, 2025 (GLOBE NEWSWIRE) -- SPR announced the peer-reviewed publication of additional survey data demonstrating the impact of SPR® SPRINT® PNS treatment on chronic shoulder pain. Shoulder pain is one of the most common locations of chronic pain for millions of Americans, significantly impacting their quality of life, ability to conduct daily activities, perform at work, and can lead to long-term disability. Published in Pain and Therapy, 'Durable Shoulder Pain Relief and Avoidance of Surgery Up To 5 Years Following 60-Day PNS Treatment' evaluates the long-term outcomes and sustained durability following the use of the SPRINT PNS System for chronic shoulder pain. The cross-sectional survey included 489 patients, ranging from six months to five years post start of treatment, to assess sustained pain relief and the need for further interventions. Safety outcomes were not specifically analyzed in the long-term follow-up survey. Highlights include: Among survey participants, who had a mean follow-up duration of 21 months, 83 percent (405/489) required no subsequent interventions (radiofrequency ablation, permanent implant, or surgery) following 60-day PNS 87 percent (353/405) of those patients reporting no subsequent intervention were defined as long-term responders, with sustained improvement in at least one domain including pain (≥50% relief) and/or clinically meaningful improvements (at least minimally improved) in quality of life, function, or sleep Mean pain relief among long-term responders was 68 percent Outcomes were consistent across follow-up durations up to five years and causes of chronic shoulder pain Review the full publication in Pain and Therapy here. 'The durability of outcomes over time and across a wide range of shoulder pain causes supports our belief that 60-day PNS is both a clinically effective and potentially economically advantageous approach for appropriate patients,' said Maria Bennett, President, CEO, and Founder of SPR. 'Helping patients return to their daily life is our focus. Avoiding or delaying more invasive procedures is a meaningful benefit for patients personally and financially.' About the SPRINT PNS System The SPR® SPRINT® PNS System marks an innovative shift in the treatment of pain. Our breakthrough, 60-day treatment is a First-Line PNS™ option uniquely proposed to recondition the central nervous system to provide significant and sustained relief from chronic pain — without a permanent implant, nerve destruction or the risk of addiction. The system has been studied extensively for low back pain, knee pain, shoulder pain, post-amputation pain, and chronic and acute postoperative pain, is cleared for use up to 60 days, and is recognized by leading pain management centers. Market research indicates that this breakthrough neuromodulation treatment is a patient-preferred alternative to more invasive options. The SPRINT PNS System is indicated for up to 60 days for: Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post-traumatic pain; symptomatic relief of postoperative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information, see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only. For additional information regarding safety and efficacy, visit: SPR Safety Information. About SPR SPR is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain. Backed by the largest body of clinical evidence in peripheral nerve stimulation for the treatment of pain, SPR has demonstrated commercial demand in untapped peripheral (shoulder and knee) and back pain markets and built an incredibly strong foundation for commercial growth. Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR's Senior Management team includes experienced industry veterans with nearly 200 years of collective pain market and MedTech expertise, all driven by our purpose – to improve the quality of patients' lives by providing them with a minimally invasive, drug-free, surgery-free solution to manage their acute and chronic pain. SPR – Solutions for pain. Inspired by life.™ More information can be found at SPR Contacts:Dave FolkensPublic Relations
Yahoo
19-05-2025
- Business
- Yahoo
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations Poster Presentations on New Pivotal Phase 3 Analyses Underscore Tanruprubart's Rapid and Sustained Treatment Effect and Improvement in Quality of Life Compared to Placebo BRISBANE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today presented oral and poster presentations highlighting improved outcomes with tanruprubart (formerly ANX005) at the 2025 Peripheral Nerve Society (PNS) Annual Meeting being held May 17-20, 2025 in Edinburgh, UK. GBS is a neuromuscular emergency and rare autoimmune disease that affects at least 150,000 people worldwide each year, with no FDA-approved therapies. In its acute phase, GBS rapidly progresses toward severe weakness that can lead to sudden and complete paralysis, often requiring intensive care and mechanical ventilation. Tanruprubart is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade, with a single infusion to halt ongoing neuroinflammation and nerve damage in the early phase of GBS to improve and expedite overall recovery. 'These compelling clinical results presented at PNS depict how a rapid gain in muscle strength can lead to a better state of health with a single infusion of tanruprubart in a real world setting,' said Henk-André Kroon, M.D., senior vice president of Translational Medicine at Annexon. 'Currently, outcomes for GBS patients around the world remain poor, and we are grateful to our collaborators at IGOS for conducting this prespecified analysis showing the significant improvement with tanruprubart compared to standard of care. As the potential first targeted immunotherapy in GBS, we are eager to move tanruprubart forward for patients in need, with the aim of transforming the global treatment landscape for GBS.' RWE Findings Demonstrate Benefits with Tanruprubart over Current Standard of Care in Matched Patient Populations Results of the pivotal Phase 3 trial are reinforced by a RWE study that matched tanruprubart-treated patients from the pivotal Phase 3 trial with patients predominantly from western countries included in the IGOS registry who were treated with current standard of care, intravenous immunoglobulin (IVIg) or plasma exchange (PE). In the RWE study, tanruprubart showed a rapid increase in muscle function resulting in a sustained and more complete recovery compared to IVIg or PE: By Week 1, patients treated with tanruprubart showed approximately a ten-point improvement in muscle strength over patients treated with IVIg or PE, a clinically meaningful benefit as measured by Medical Research Council (MRC) sumscore and an indicator for future recovery potential Patients treated with tanruprubart were approximately three times more likely to be in a better state of health than patients on IVIg or PE on the GBS-Disability Scale (GBS-DS) at Weeks 4, 8, and 26 New Pivotal Phase 3 Trial Analyses Reinforce the Rapid and Sustained Clinical Benefits of a Single Dose of Tanruprubart Tanruprubart 30 mg/kg halted inflammation and nerve damage resulting in clinical benefits as early as Week 1, including rapid improvements in muscle strength, mobility, balance, and coordination that were maintained through Week 26 Tanruprubart-treated patients rapidly regained the ability to move independently, do personal tasks, and return to a range of routine daily living activities Tanruprubart demonstrated a greater degree of efficacy amongst patients with disease characteristics more commonly observed in western countries, supporting the potential of tanruprubart to benefit patients worldwide Presentations are available on the publications page of the company's website. About Tanruprubart (formerly ANX005) Annexon's lead investigational therapy, tanruprubart, is a first-of-its kind selective, targeted and rapid-acting agent designed to reduce inflammation and nerve damage by stopping C1q activity in the peripheral and central nervous systems. In GBS, tanruprubart is designed to seek out C1q and prevent its binding to targets on peripheral nerves. Tanruprubart is administered intravenously and has been observed to act almost immediately in blocking C1q function. The aim of an effective treatment in GBS is to rapidly stop the autoimmune damage on nerve cells, allowing patients to regain muscle strength sooner and to regain independence and return to pre-illness activities. Tanruprubart has received both Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration as well as orphan drug designation from the European Medicines Agency for the treatment of GBS. About Guillain-Barré Syndrome (GBS)GBS is a rare neuromuscular emergency resulting from an acute autoantibody and classical complement-mediated attack on peripheral nerves that generally occurs post-infection in otherwise healthy persons. It is an acute, rapidly progressive disease with a narrow timeframe for therapeutic intervention. GBS results in the hospitalization of more than 22,000 people annually in the U.S. and Europe. In its acute phase, the peripheral nerve damage progresses rapidly, causing sudden and complete neuromuscular paralysis that can lead to significant morbidity, disability and mortality. Currently, there are no approved treatments for GBS in the U.S. The long-term disease burden associated with GBS has led to a multi-billion-dollar annual economic cost to the U.S. healthcare system alone. More information about the impact of GBS is available at About AnnexonAnnexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement's potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade in disease before it starts. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon's mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as 'aim,' 'anticipate,' 'assume,' 'contemplate,' 'continue,' 'could,' 'design,' 'due,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'objective,' 'plan,' 'positioned,' 'potential,' 'predict,' 'seek,' 'should,' 'target,' 'will,' 'would' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the ability of tanruprubart to block C1q activity in the peripheral and central nervous systems with a single infusion; the potential therapeutic benefit of tanruprubart, if approved, compared to IVIg/plasma exchange or existing therapies; the clinical and regulatory status of tanruprubart; the planned presentation of RWE at upcoming conferences; the ability to translate the results of the RWE study to a broad population of GBS patients; the impacts of the new education campaign (Move GBS Forward™); the potential benefits from treatment with anti-C1q therapy; and continuing advancement of the company's portfolio. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company's history of net operating losses; the company's ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company's product candidates; the effects of public health crises on the company's clinical programs and business operations; the company's ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company's product candidates; the company's reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company's ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled 'Risk Factors' contained in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company's other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Joyce AllaireLifeSci Advisorsjallaire@ Media Contact: Sheryl SeapyReal Chemistry949-903-4750sseapy@
Yahoo
18-05-2025
- Business
- Yahoo
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compared to Current Standards of Care in Matched Patient Populations New Analyses of Phase 3 Trial Highlight Tanruprubart's Early and Durable Treatment Effect and Improvement in Quality of Life in Patients with GBS BRISBANE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced oral and poster presentations highlighting improved outcomes with tanruprubart (formerly ANX005) at the 2025 Peripheral Nerve Society (PNS) Annual Meeting at the Edinburgh International Conference Centre being held May 17-20, 2025 in Edinburgh, UK. GBS is a neuromuscular emergency and rare autoimmune disease with no FDA-approved therapies that is characterized by rapidly progressing and severe weakness that can lead to complete paralysis, often requiring intensive care and mechanical ventilation. Tanruprubart is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade, with a single infusion to halt ongoing neuroinflammation and nerve damage in the acute phase of GBS to improve and expedite overall recovery. Oral Presentation 'Comparative Effectiveness in IGOS: ANX005 Versus Intravenous Immunoglobulin or Plasma Exchange for Guillain-Barré Syndrome' IGOS Presenter: Eveline Wiegers, M.D., Ph.D. Date/Time: Monday, May 19, from 3:55 pm to 4:10 pm British Summer Time (BST) Poster Presentations 'Linking Early Complement Inhibition to Long-Term Outcomes in GBS: Objective Measures Support Tanruprubart (ANX005) Efficacy' Presenter: Glenn Morrison, Ph.D. Date/Time: Sunday May 18, from 2:30 pm to 3:20 pm BST 'Tanruprubart (ANX005) Improves Health-related Quality of Life in Patients with Guillain-Barré Syndrome Compared to Placebo' Presenter: Glenn Morrison, Ph.D. Date/Time: Monday, May 19, from 2:10 pm to 3:10 pm BST. Poster also selected as a flash oral presentation from 5:30 pm to 5:35 pm BST. 'Efficacy of Tanruprubart (ANX005) for Treatment of Guillain-Barré Syndrome in a Broad Spectrum of Patients' Presenter: Henk-André Kroon, M.D. Date/Time: Monday May 19, from 2:10 pm to 3:10 pm BST About Tanruprubart (formerly ANX005)Annexon's lead investigational therapy, tanruprubart, is a first-of-its kind selective, targeted and rapid-acting agent designed to reduce inflammation and nerve damage by stopping C1q activity in the peripheral and central nervous systems. In GBS, tanruprubart is designed to seek out C1q and prevent its binding to targets on peripheral nerves. Tanruprubart is administered intravenously and has been observed to act almost immediately in blocking C1q function. The aim of an effective treatment in GBS is to rapidly stop the autoimmune damage on nerve cells, allowing patients to regain muscle strength sooner and to regain independence and return to pre-illness activities. Tanruprubart has received both Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration as well as orphan drug designation from the European Medicines Agency for the treatment of GBS. About Guillain-Barré Syndrome (GBS)GBS is a rare neuromuscular emergency resulting from an acute autoantibody and classical complement-mediated attack on peripheral nerves that generally occurs post-infection in otherwise healthy persons. It is an acute, rapidly progressive disease with a narrow timeframe for therapeutic intervention. GBS results in the hospitalization of more than 22,000 people annually in the U.S. and Europe. The peripheral nerve damage progresses rapidly, causing acute neuromuscular paralysis that can lead to significant morbidity, disability and mortality. Currently, there are no approved treatments for GBS in the U.S. The long-term disease burden associated with GBS has led to a multi-billion-dollar annual economic cost to the U.S. healthcare system alone. More information about the impact of GBS is available at About AnnexonAnnexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement's potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade in disease before it starts. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon's mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit Forward Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'design,' 'due,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'objective,' 'plan,' 'positioned,' 'potential,' 'predict,' 'seek,' 'should,' 'suggest,' 'target,' 'on track,' 'will,' 'would' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, the ability of tanruprubart (formerly ANX005) to stop C1q activity in the peripheral and central nervous systems; the clinical and regulatory status of ANX005; and the potential therapeutic benefit of ANX005; the potential benefits from treatment with anti-C1q therapy; and continuing advancement of the company's portfolio. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company's history of net operating losses; the company's ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company's product candidates; the effects of public health crises on the company's clinical programs and business operations; the company's ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company's product candidates; the company's reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company's ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled 'Risk Factors' contained in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company's other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact:Joyce AllaireLifeSci Advisors, LLCjallaire@ Media Contact:Sheryl SeapyReal Chemistry949-903-4750sseapy@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
